Trump Cuts Prices on Ozempic and Wegovy in Deal With GLP-1 Weight Loss Drug Makers

President Trump announced a deal with Eli Lilly and Novo Nordisk to significantly reduce the prices of GLP-1 medications, including Ozempic and Wegovy. Under the new pricing, monthly costs can drop to about $250, with future drugs priced at a capped rate of $149. This initiative is part of a Medicare pilot program that will now cover these weight loss drugs for eligible patients, who will pay a co-pay of roughly $50. This move aims to address the high costs that previously limited insurance coverage for these medications. Trump emphasized that this project bears his name and will result in better access to critical treatments for obesity, which is linked to numerous health issues and high healthcare costs. Additionally, the companies plan to invest in U.S. manufacturing of these drugs to increase supply. The agreement is expected to be a significant step in expanding access to essential obesity and diabetes treatments for millions of Americans, with implementation anticipated to begin in mid-2026.

Source 🔗